Easton Pharmaceuticals to Participate in a Casino and Hotel Resort Project in Europe with Projected Revenues in Excess of 77 Million Euro Per Annum

TORONTO, ON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Easton Pharmaceuticals Inc. (OTC: EAPH) announces that it has entered into a Letter of Intent to acquire an interest or participate in the development of a casino and hotel resort in Europe. The project will consist of 538 Hotel Rooms & VIP Suites, 5 Restaurants & Food Court, a Convention Centre, a Shopping Mall, Showroom, Nightclub, Health Spa Facility, a 1,000 Slot Machines and 50 Table Game Casino, and a 504 Car Covered Parking Garage.

As part of the Company’s plan to enter more lucrative market segments, Easton has entered into a Letter of Intent with the US based gaming arm of a Canadian holding and investment company, to participate in the development of a casino and hotel resort property in Europe. The revenues are expected to be in excess of 77 Million Euro per year.

“This casino and hotel resort project will be a high-end development in anidyllicriver location and will be the second Casino Hotel Resort Easton intends to participate in as part of our global expansion plan. It is expected to be one of the most prominent properties when it opens. I am excited for the prospects of having Easton participate in such an incredible opportunity,” stated Mr. Evan Karras. Mr. Karras further commented, “This Agreement is one of several that Easton is entering into for gaming globally and will bring the Company and its shareholders tremendous value and growth.”  Easton is currently negotiating its participation in the project and will provide assistance with the development, management and financing of the project. The property offers substantial upside, both in the gaming sector, as well as the hospitality sector.

The negotiations are anticipated to be completed within the next 30 days with additional detailed information to be provided in the coming weeks or as it becomes readily available and approved for release.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts. As part of its strategic growth plan, the Company will be entering new lucrative global market segments, some of which include Gaming, Real Estate and Hospitality.

For More Information On Easton and Affiliated and Partner Companies Visit:

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.


Contact Data